Abacavir GPO

Abacavir GPO





Concise Prescribing Info
Abacavir sulfate
HIV infection in combination w/ other antiretroviral agents.
Dosage/Direction for Use
Adult & adolescent weighing at least 30 kg 600 mg daily. May be administered as 300 mg bid or 600 mg once daily. Childn 3 mth & weighing at least 30 kg 300 mg bid or 600 mg once daily, >21 to <30 kg 450 mg daily, or 150 mg in the morning & 300 mg in the evening, 14-21 kg 300 mg daily, or 150 mg bid. Mild hepatic function impairment (Child-Pugh score 5-6) 200 mg bid.
May be taken with or without food.
Hypersensitivity. Moderate or severe hepatic impairment.
Special Precautions
Screen patient for HLA-B*5701 allele prior to initiating & re-initiation therapy. HLA-B*5701-positive patients. Patients w/ known risk factors for liver disease. Discontinue treatment if hypersensitivity, lactic acidosis or pronounced hepatotoxicity develops. Immune reconstitution syndrome. Fat redistribution. Consider risk of CHD in patients w/ modifiable risk factors (eg, HTN, hyperlipidemia, DM & smoking). Pregnancy & lactation. Childn <3 mth.
Adverse Reactions
Hypersensitivity reactions; abdominal pain, anaphylaxis, arthralgia, conjunctivitis, diarrhea, edema, fatigue, fever, headache, hepatic failure, lethargy, lymphadenopathy, malaise, mouth ulcerations, myalgia, myolysis, nausea, paresthesia, rash (including erythema multiforme), renal failure, resp symptoms (eg, adult resp distress syndrome, cough, dyspnea, pharyngitis, resp failure) & vomiting.
Drug Interactions
Increased levels/effects w/ ganciclovir, valganciclovir & ribavirin. Retinoids.
MIMS Class
ATC Classification
J05AF06 - abacavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Abacavir GPO FC tab 300 mg
6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in